← FDA DRUG APPROVALS

FDA ANDA · ANDA077538

FLUTICASONE PROPIONATE

Sponsor: APOTEX

APPLICATION
ANDA077538
TYPE
ANDA
ORIGINAL APPROVAL
2007-09-12
LATEST ACTION
2020-08-13
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Prescription

Products

FLUTICASONE PROPIONATEPrescription
FLUTICASONE PROPIONATE 0.05MG/SPRAY · SPRAY, METERED · NASAL

Approval history

2020-08-13Labeling · Supplement 31 · standardAP
2017-04-18Manufacturing (CMC) · Supplement 19 · unknownAP
2017-04-18Labeling · Supplement 15 · standardAP
2007-09-12OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →